# FDA Approves Lumvoa (veligrotug-vvze) for Thyroid Eye Disease

> fda · REPORTED · 2026-06-26

On June 26, 2026, the FDA approved Lumvoa (veligrotug-vvze), an insulin-like growth factor-1 receptor inhibitor developed by Viridian Therapeutics, for the treatment of thyroid eye disease. The approval adds a new targeted biologic option to the thyroid eye disease landscape.

- Company: Viridian Therapeutics
- Sector: therapeutics
- Primary source: https://www.drugs.com/newdrugs.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.